These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38239644)

  • 1. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients.
    Kovalenko I; Lynn Ng W; Geng Y; Wang Y; Msaouel P; Bhatia S; Grivas P; Benkhadra R; Alhalabi O
    Front Oncol; 2023; 13():1238517. PubMed ID: 38239644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
    Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
    Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.
    Xu T; Liu Y; Lu X; Liang J
    Front Immunol; 2022; 13():1039020. PubMed ID: 36439117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis.
    Shen X; Yang J; Qian G; Sheng M; Wang Y; Li G; Yan J
    Front Oncol; 2024; 14():1391724. PubMed ID: 38826783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
    Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
    PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
    Park R; Lopes L; Cristancho CR; Riano IM; Saeed A
    Front Oncol; 2020; 10():258. PubMed ID: 32257944
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
    Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
    Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
    Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
    Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Da L; Teng Y; Wang N; Zaguirre K; Liu Y; Qi Y; Song F
    Front Pharmacol; 2019; 10():1671. PubMed ID: 32082164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
    Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
    Zheng J; Huang B; Xiao L; Wu M; Li J
    Front Oncol; 2022; 12():821626. PubMed ID: 36568203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
    Lees JS; Dobbin SJH; Elyan BMP; Gilmour DF; Tomlinson LP; Lang NN; Mark PB
    Nephrol Dial Transplant; 2023 Jun; 38(7):1666-1681. PubMed ID: 36318455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Auranen A; Powell MA; Sukhin V; Landrum LM; Ronzino G; Buscema J; Bauerschlag D; Lalisang R; Bender D; Gilbert L; Armstrong A; Safra T; Nevadunsky N; Sebastianelli A; Slomovitz B; Ring K; Coleman R; Podzielinski I; Stuckey A; Teneriello M; Gill S; Pothuri B; Willmott L; Sharma S; Dabrowski C; Antony G; Stevens S; Mirza MR; Fleming E
    Ther Adv Med Oncol; 2024; 16():17588359241277656. PubMed ID: 39346117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Dang S; Li X; Liu H; Zhang S; Li W
    Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis.
    Tang Q; Wu D; Huang H; Fang H; Wu Y; Liu F; Li N
    Front Pharmacol; 2023; 14():1093194. PubMed ID: 37180706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.